WHAT IS CLAIMED IS

1. A method of inhibiting human stearoyl-CoA desaturase (hSCD) activity comprising contacting a source of hSCD with a compound of formula (I):



(I)

wherein:

x and y are each independently 1, 2 or 3;

W is -O-, -C(O)O-, -N(R^1)-, -S(O)$_t$- (where t is 0, 1 or 2), -N(R^1)S(O)$_2$-, -OC(O)- or -C(O)-;

V is -C(O)-, -C(S)-, -C(O)N(R^1)-, -C(O)O-, -S(O)$_2$-, -S(O)$_2$N(R^1)- or -C(R^{11})H-;

each R^1 is independently selected from the group consisting of hydrogen, C_1-C_{12}alkyl, C_2-C_{12}hydroxyalkyl, C_4-C_{12}cycloalkylalkyl and C_7-C_{19}aralkyl;

R^2 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{19}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl, and C_3-C_{12}heteroarylalkyl;

or R^2 is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

R^3 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{19}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl and C_3-C_{12}heteroarylalkyl;

or R^3 is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

R^4 and R^5 are each independently selected from hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N(R^{13})$_2$;

R^6, R^{6a}, R^7, R^{7a}, R^8, R^{8a}, R^9 and R^{9a} are each independently selected

from hydrogen or C_1-C_3alkyl;

or R^7 and R^{7a} together, or $R^8$and R^{8a} together, or $R^9$and R^{9a} together, or R^6 and R^{6a} together are an oxo group, provided that when V is -C(O)-, $R^7$and R^{7a} together or R^8 and R^{8a} together do not form an oxo group, while the remaining R^7, R^{7a}, R^8, R^{8a}, R^9, R^{9a}, R^6 and R^{6a} are each independently selected from hydrogen or C_1-C_3alkyl;

or one of R^6, R^{6a}, R^7, and R^{7a} together with one of R^8, R^{8a}, R^9 and R^{9a} form an alkylene bridge, while the remaining R^6, R^{6a}, R^7, R^{7a}, R^8, R^{8a}, R^9, and R^{9a} are each independently selected from hydrogen or C_1-C_3alkyl;

R^{11} is hydrogen or C_1-C_3alkyl; and

each R^{13} is independently selected from hydrogen or C_1-C_6alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

2. A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of formula (I):



(I)

wherein:

x and y are each independently 1, 2 or 3;

W is -O-, -C(O)O-, -N(R^1)-, -S(O)$_t$- (where t is 0, 1 or 2), -N(R^1)S(O)$_2$-, -OC(O)- or -C(O)-;

V is -C(O)-, -C(S)-, -C(O)N(R^1)-, -C(O)O-, -S(O)$_2$-, -S(O)$_2$N(R^1)- or -C(R^{11})H-;

each R^1 is independently selected from the group consisting of hydrogen, C_1-C_{12}alkyl, C_2-C_{12}hydroxyalkyl, C_4-C_{12}cycloalkylalkyl and C_7-C_{19}aralkyl;

R^2 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl,

C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{19}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl, and C_3-C_{12}heteroarylalkyl;

or R^2 is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

R^3 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{19}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl and C_3-C_{12}heteroarylalkyl;

or R^3 is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

R^4 and R^5 are each independently selected from hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or $-N(R^{13})_2$;

R^6, R^{6a}, R^7, R^{7a}, R^8, R^{8a}, R^9 and R^{9a} are each independently selected from hydrogen or C_1-C_3alkyl;

or R^7 and R^{7a} together, or $R^8$and R^{8a} together, or $R^9$and R^{9a} together, or R^6 and R^{6a} together are an oxo group, provided that when V is -C(O)-, $R^7$and R^{7a} together or R^8 and R^{8a} together do not form an oxo group, while the remaining R^7, R^{7a}, R^8, R^{8a}, R^9, R^{9a}, R^6 and R^{6a} are each independently selected from hydrogen or C_1-C_3alkyl;

or one of R^6, R^{6a}, R^7, and R^{7a} together with one of R^8, R^{8a}, R^9 and R^{9a} form an alkylene bridge, while the remaining R^6, R^{6a}, R^7, R^{7a}, R^8, R^{8a}, R^9, and R^{9a} are each independently selected from hydrogen or C_1-C_3alkyl;

R^{11} is hydrogen or C_1-C_3alkyl; and

each R^{13} is independently selected from hydrogen or C_1-C_6alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

3. The method of Claim 2 wherein the mammal is a human.

4. The method of Claim 3 wherein the disease or condition is selected from the group consisting of Type II diabetes, impaired glucose tolerance, insulin resistance, obesity, fatty liver, non-alcoholic steatohepatitis, dyslipidemia and metabolic syndrome and any combination of these.

5. The method of Claim 4 wherein the disease or condition is Type II diabetes.

6. The method of Claim 4 wherein the disease or condition is obesity.

7. The method of Claim 4 wherein the disease or condition is metabolic syndrome.

8. The method of Claim 4 wherein the disease or condition is fatty liver.

9. The method of Claim 4 wherein the disease or condition is non-alcoholic steatohepatitis.

10. A compound of formula (Ia):



(Ia)

wherein:

x and y are each independently 1, 2 or 3;

W is -O-, -C(O)O-, -N(R^1)-, -S(O)$_t$- (where t is 0, 1 or 2), -N(R^1)S(O)$_2$-, -OC(O)- or -C(O)-;

V is -C(O)-, -C(S)-, -C(O)N(R^1)-, -C(O)O-, -S(O)$_2$-, -S(O)$_2$N(R^1)- or -C(R^{11})H-;

each R^1 is independently selected from the group consisting of hydrogen, C_1-C_{12}alkyl, C_2-C_{12}hydroxyalkyl, C_4-C_{12}cycloalkylalkyl and C_7-C_{19}aralkyl;

R^2 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{19}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl, and C_3-C_{12}heteroarylalkyl, provided that, when W is -C(O)-, R^2 can not be C_1-C_6alkyl substituted by -S(O)$_t$$R^{14}$ where R^{14} is hydrogen, C_1-C_6alkyl,

C_7-C_{12}aralkyl, pyrazinyl, pyridinonyl, pyrrolidionyl or imidazolyl;

or R^2 is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

R^3 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{19}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl and C_3-C_{12}heteroarylalkyl;

or R^3 is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

R^4 and R^5 are each independently selected from hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N(R^{13})$_2$;

R^6, R^{6a}, R^7, R^{7a}, R^8, R^{8a}, R^9 and R^{9a} are each independently selected from hydrogen or C_1-C_3alkyl;

or R^7 and R^{7a} together, or $R^8$and R^{8a} together, or $R^9$and R^{9a} together, or R^6 and R^{6a} together are an oxo group, provided that when V is -C(O)-, $R^7$and R^{7a} together or R^8 and R^{8a} together do not form an oxo group, while the remaining R^7, R^{7a}, R^8, R^{8a}, R^9, R^{9a}, R^6 and R^{6a} are each independently selected from hydrogen or C_1-C_3alkyl;

or one of R^6, R^{6a}, R^7, and R^{7a} together with one of R^8, R^{8a}, R^9 and R^{9a} form an alkylene bridge, while the remaining R^6, R^{6a}, R^7, R^{7a}, R^8, R^{8a}, R^9, and R^{9a} are each independently selected from hydrogen or C_1-C_3alkyl;

R^{11} is hydrogen or C_1-C_3alkyl; and

each R^{13} is independently selected from hydrogen or C_1-C_6alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

11. The compound of Claim 10 wherein:

x and y are each 1;

W is -O-;

V is -C(O)- or -C(S)-;

R^2 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{19}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl,

C_1-C_{12}heteroaryl, and C_3-C_{12}heteroarylalkyl;

R^3 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{19}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl and C_3-C_{12}heteroarylalkyl;

R^4 and R^5 are each hydrogen; and

R^6, R^{6a}, R^7, R^{7a}, R^8, R^{8a}, R^9 and R^{9a} are each hydrogen.

12. The compound of Claim 11 wherein:

V is -C(O)-;

R^2 is C_7-C_{12}aralkyl optionally substituted by one or more substituents selected from halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy;

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl, C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, -$N(R^{12})_2$, -$OC(O)R^{12}$, -$C(O)OR^{12}$, -$S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and

each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

13. The compound of Claim 12 wherein:

R^2 is C_7-C_{12}aralkyl optionally substituted by one or more substituents selected from halo, C_1-C_6alkyl, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy; and

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy.

14. The compound of Claim 13, namely, [4-(6-Phenethyloxy-pyridazin-3-yl)-piperazin-1-yl]-(2-trifluoromethyl-phenyl)-methanone.

15. The compound of Claim 11 wherein:

V is -C(O)-;

R^2 is C_1-C_{12}alkyl or C_2-C_{12}alkenyl;

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl, C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, -$N(R^{12})_2$, -$OC(O)R^{12}$, -$C(O)OR^{12}$, -$S(O)_2N(R^{12})_2$,

cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and

each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

16. The compound of Claim 11 wherein:

V is -C(O)-;

R^2 is C_3-C_{12}cycloalkyl or C_4-C_{12}cycloalkylalkyl;

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl, C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, -$N(R^{12})_2$, -$OC(O)R^{12}$, -$C(O)OR^{12}$, -$S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and

each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

17. The compound of Claim 16 wherein:

R^2 is C_4-C_{12}cycloalkylalkyl; and

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy.

18. The compound of Claim 17, namely, {4-[6-(2-Cyclopropyl-ethoxy)-pyridazin-3-yl]-piperazin-1-yl}-(2-trifluoromethyl-phenyl)-methanone.

19. The compound of Claim 10 wherein:

x and y are each 1;

W is -$S(O)_t$- (where t is 0, 1 or 2);

V is -C(O)- or -C(S)-;

R^2 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{12}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl, and C_3-C_{12}heteroarylalkyl;

R^3 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{12}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl and C_3-C_{12}heteroarylalkyl;

R^4 and R^5 are each hydrogen; and

R^6, R^{6a}, R^7, R^{7a}, R^8, R^{8a}, R^9 and R^{9a} are each hydrogen.

20. The compound of Claim 19 wherein:

V is -C(O)-;

R^2 is C_7-C_{12}aralkyl optionally substituted by one or more substituents selected from halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy;

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl, C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, -$N(R^{12})_2$, -$OC(O)R^{12}$, -$C(O)OR^{12}$, -$S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and

each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

21. The compound of Claim 20 wherein:

R^2 is C_7-C_{12}aralkyl optionally substituted by one or more substituents selected from halo, C_1-C_6alkyl, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy; and

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy.

22. The compound of Claim 21 selected from the group consisting of the following:

[4-(6-Phenethylsulfanyl-pyridazin-3-yl)-piperazin-1-yl]-(2-trifluoromethyl-phenyl)-methanone;

{4-[6-(2-Phenyl-ethanesulfinyl)-pyridazin-3-yl]-piperazin-1-yl}-(2-trifluoromethyl-phenyl)-methanone; and

{4-[6-(2-Phenyl-ethanesulfonyl)-pyridazin-3-yl]-piperazin-1-yl}-(2-trifluoromethyl-phenyl)-methanone.

23. The compound of Claim 19 wherein:

V is -C(O)-;

R^2 is C_1-C_{12}alkyl or C_2-C_{12}alkenyl;

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl, C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, -$N(R^{12})_2$, -$OC(O)R^{12}$, -$C(O)OR^{12}$, -$S(O)_2N(R^{12})_2$,

cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and

each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

24. The compound of Claim 23 wherein R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy.

25. The compound of Claim 24, namely, {4-[6-(3-Methyl-butylsulfanyl)-pyridazin-3-yl]-piperazin-1-yl}-(2-trifluoromethyl-phenyl)-methanone.

26. The compound of Claim 10 wherein:

x and y are each 1;

W is -N(R^1)-;

V is -C(O)- or -C(S)-;

R^1 is hydrogen or C_1-C_6alkyl;

R^2 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{12}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl, and C_3-C_{12}heteroarylalkyl;

R^3 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{12}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl and C_3-C_{12}heteroarylalkyl;

R^4 and R^5 are each hydrogen; and

R^6, R^{6a}, R^7, R^{7a}, R^8, R^{8a}, R^9 and R^{9a} are each hydrogen.

27. The compound of Claim 26 wherein:

V is -C(O)-;

R^1 is hydrogen or C_1-C_6alkyl;

R^2 is C_7-C_{12}aralkyl optionally substituted by one or more substituents selected from halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy;

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl,

C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, -$N(R^{12})_2$, -$OC(O)R^{12}$, -$C(O)OR^{12}$, -$S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and

each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

28. The compound of Claim 27 wherein R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy.

29. The compound of Claim 28 selected from the group consisting of the following:

[4-(6-Phenethylamino-pyridazin-3-yl)-piperazin-1-yl]-(2-trifluoromethyl-phenyl)-methanone; and

{4-[6-(Methyl-phenethyl-amino)-pyridazin-3-yl]-piperazin-1-yl}-(2-trifluoromethyl-phenyl)-methanone.

30. The compound of Claim 26 wherein:

V is -C(O)-;

R^1 is hydrogen or C_1-C_6alkyl;

R^2 is C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_3-C_{12}cycloalkyl or C_4-C_{12}cycloalkylalkyl;

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl, C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, -$N(R^{12})_2$, -$OC(O)R^{12}$, -$C(O)OR^{12}$, -$S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and

each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

31. The compound of Claim 10 wherein:

x and y are each 1;

W is -$N(R^1)S(O)_2$-;

V is -C(O)- or -C(S)-;

R^1 is hydrogen or C_1-C_6alkyl;

R^2 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl,

C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{12}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl, and C_3-C_{12}heteroarylalkyl;

R^3 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{12}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl and C_3-C_{12}heteroarylalkyl;

R^4 and R^5 are each hydrogen; and

R^6, R^{6a}, R^7, R^{7a}, R^8, R^{8a}, R^9 and R^{9a} are each hydrogen.

32. The compound of Claim 31 wherein:

V is -C(O)-;

R^1 is hydrogen or C_1-C_6alkyl;

R^2 is C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_3-C_{12}cycloalkyl or C_4-C_{12}cycloalkylalkyl;

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl, C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, -$N(R^{12})_2$, -$OC(O)R^{12}$, -$C(O)OR^{12}$, -$S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and

each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

33. The compound of Claim 32 wherein:

R^2 is C_1-C_{12}alkyl; and

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy.

34. The compound of Claim 33, namely, Propane-1-sulfonic acid {6-[4-(2-trifluoromethyl-benzoyl)-piperazin-1-yl]-pyridazin-3-yl}-amide.

35. The compound of Claim 31 wherein:

V is -C(O)-;

R^1 is hydrogen or C_1-C_6alkyl;

R^2 is C_7-C_{12}aralkyl optionally substituted by one or more substituents selected from halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy;

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl, C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, -$N(R^{12})_2$, -$OC(O)R^{12}$, -$C(O)OR^{12}$, -$S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and

each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

36. A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 10.

37. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of Claim 10.